Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guobang PharmaSHSE:605507 -1.29%88 FCF Margin % is 6.69% as of Mar. 2026, which is 79% above its 10-year median of 3.74. GuruFocus rates SHSE:605507 with a GF Score™ of 88/100 and a GF Value™ of ¥16.00 (Fairly Valued). The stock has 4 warning signs investors should review. Among 963 Drug Manufacturers companies, Guobang Pharma ranks better than 77.05% on this metric.
The historical rank and industry rank for Guobang Pharma's FCF Margin % or its related term are showing as below:
SHSE:605507'
s FCF Margin % Range Over the Past 10 Years
Min: -13.86 Med: 3.74 Max: 12.74
Current: 12.74
During the past 9 years, the highest FCF Margin % of Guobang Pharma was 12.74%. The lowest was -13.86%. And the median was 3.74%.
SHSE:605507's FCF Margin % is ranked better than 77.05% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.59
vs SHSE:605507: 12.74
Guobang Pharma FCF Margin % Related Terms
Guobang Pharma FCF Margin % Historical Data
* Premium members only.
The historical data trend for Guobang Pharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Guobang Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guobang Pharma FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Guobang Pharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Guobang Pharma's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guobang Pharma (SHSE:605507) has a FCF Margin % of 6.69% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Guobang Pharma and its competitors. This is 79% above median its historical median of 3.74. According to the industry distribution chart, Guobang Pharma ranks #221 out of 963 companies in the Drug Manufacturers industry, placing it in the top 22.9%.
Is Guobang Pharma's FCF Margin % too high?
Guobang Pharma's current FCF Margin % of 6.69% is 79% above median its 10-year median of 3.74. The Drug Manufacturers industry median FCF Margin % is 2.59. Guobang Pharma's value of 6.69% is 158.3% above this industry median. Based on the distribution chart, Guobang Pharma ranks #221 out of 963 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Guobang Pharma has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guobang Pharma's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Guobang Pharma ranks #221 out of 963 companies for FCF Margin %. This places Guobang Pharma in the top 23% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.59. Guobang Pharma's value of 6.69% is 158.3% above this benchmark. While the company's 10-year median is 3.74 vs. the industry median of 2.59, Guobang Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.59, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guobang Pharma's current FCF Margin % of 6.69% is 158.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Guobang Pharma and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guobang Pharma's current FCF Margin % is 6.69%, which is 79% above median its own 10-year median of 3.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guobang Pharma stock overvalued right now?
Based on GuruFocus' analysis, Guobang Pharma (SHSE:605507) is currently considered Fairly Valued. The stock's GF Value™ is ¥16.00, compared to a current price of ¥16.09 — trading 0.6% above its estimated fair value. The current FCF Margin % is 6.69%, which is 79% above median its 10-year median of 3.74 and 158.3% above the Drug Manufacturers industry median of 2.59. Guobang Pharma's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Guobang Pharma (SHSE:605507), the current FCF Margin % is 6.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guobang Pharma (SHSE:605507) Overvalued in 2026?
Based on GuruFocus' analysis, Guobang Pharma stock appears to be overvalued.
The current stock price of ¥16.09 is trading 0.6% above its estimated GF Value™ of ¥16.00.
GuruFocus considers Guobang Pharma to be Fairly Valued.
Key valuation signals for SHSE:605507:
FCF Margin %: 6.69% (79% above median its 10-year median of 3.74)
GF Value™: ¥16.00 vs. price of ¥16.09 (0.6% above fair value)
Industry Position: 158.3% above the Drug Manufacturers median (#221 of 963)
No single metric tells the full story. See the SHSE:605507 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guobang Pharma Ltd is engaged in the research and development, production and sales of related products in the field of medicine and animal health products.
88GF Score
Get the complete analysis for SHSE:605507
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605507 has been successfully added to your 
